vs

Side-by-side financial comparison of Clorox (CLX) and Invesco (IVZ). Click either name above to swap in a different company.

Invesco is the larger business by last-quarter revenue ($1.7B vs $1.7B, roughly 1.0× Clorox). Clorox runs the higher net margin — 9.4% vs -58.9%, a 68.2% gap on every dollar of revenue. On growth, Invesco posted the faster year-over-year revenue change (6.2% vs 0.3%). Over the past eight quarters, Invesco's revenue compounded faster (7.1% CAGR vs -8.3%).

The Clorox Company is an American multinational manufacturer and marketer of consumer and professional products. Clorox ranked annually on the Fortune 500 list from 2000 to 2024, where it last held the #485 spot.

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

CLX vs IVZ — Head-to-Head

Bigger by revenue
IVZ
IVZ
1.0× larger
IVZ
$1.7B
$1.7B
CLX
Growing faster (revenue YoY)
IVZ
IVZ
+5.9% gap
IVZ
6.2%
0.3%
CLX
Higher net margin
CLX
CLX
68.2% more per $
CLX
9.4%
-58.9%
IVZ
Faster 2-yr revenue CAGR
IVZ
IVZ
Annualised
IVZ
7.1%
-8.3%
CLX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
CLX
CLX
IVZ
IVZ
Revenue
$1.7B
$1.7B
Net Profit
$157.0M
$-995.9M
Gross Margin
43.2%
Operating Margin
-86.2%
Net Margin
9.4%
-58.9%
Revenue YoY
0.3%
6.2%
Net Profit YoY
-15.6%
-575.8%
EPS (diluted)
$1.29
$-2.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLX
CLX
IVZ
IVZ
Q4 25
$1.7B
$1.7B
Q3 25
$1.6B
Q2 25
$2.0B
$1.5B
Q1 25
$1.7B
$1.5B
Q4 24
$1.7B
$1.6B
Q3 24
$1.8B
$1.5B
Q2 24
$1.9B
$1.5B
Q1 24
$1.8B
$1.5B
Net Profit
CLX
CLX
IVZ
IVZ
Q4 25
$157.0M
$-995.9M
Q3 25
$356.4M
Q2 25
$332.0M
$197.4M
Q1 25
$186.0M
$171.1M
Q4 24
$193.0M
$209.3M
Q3 24
$99.0M
$55.0M
Q2 24
$216.0M
$132.2M
Q1 24
$-51.0M
$141.5M
Gross Margin
CLX
CLX
IVZ
IVZ
Q4 25
43.2%
Q3 25
Q2 25
46.5%
Q1 25
44.6%
Q4 24
43.8%
Q3 24
45.8%
Q2 24
46.5%
Q1 24
42.2%
Operating Margin
CLX
CLX
IVZ
IVZ
Q4 25
-86.2%
Q3 25
16.5%
Q2 25
20.6%
14.1%
Q1 25
15.2%
18.1%
Q4 24
14.1%
19.6%
Q3 24
10.0%
6.6%
Q2 24
14.5%
13.9%
Q1 24
-2.3%
14.4%
Net Margin
CLX
CLX
IVZ
IVZ
Q4 25
9.4%
-58.9%
Q3 25
21.7%
Q2 25
16.7%
13.0%
Q1 25
11.2%
11.2%
Q4 24
11.4%
13.1%
Q3 24
5.6%
3.6%
Q2 24
11.4%
8.9%
Q1 24
-2.8%
9.6%
EPS (diluted)
CLX
CLX
IVZ
IVZ
Q4 25
$1.29
$-2.61
Q3 25
$0.66
Q2 25
$2.68
$-0.03
Q1 25
$1.50
$0.38
Q4 24
$1.54
$0.46
Q3 24
$0.80
$0.12
Q2 24
$1.74
$0.29
Q1 24
$-0.41
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLX
CLX
IVZ
IVZ
Cash + ST InvestmentsLiquidity on hand
$227.0M
$1.0B
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$-125.0M
$12.2B
Total Assets
$5.6B
$27.1B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLX
CLX
IVZ
IVZ
Q4 25
$227.0M
$1.0B
Q3 25
$973.1M
Q2 25
$167.0M
$922.7M
Q1 25
$226.0M
$821.7M
Q4 24
$290.0M
$986.5M
Q3 24
$278.0M
$1.0B
Q2 24
$202.0M
$878.5M
Q1 24
$219.0M
$895.7M
Total Debt
CLX
CLX
IVZ
IVZ
Q4 25
$1.8B
Q3 25
$1.6B
Q2 25
$2.5B
$1.9B
Q1 25
$964.8M
Q4 24
$890.6M
Q3 24
$890.3M
Q2 24
$2.5B
$890.1M
Q1 24
$1.3B
Stockholders' Equity
CLX
CLX
IVZ
IVZ
Q4 25
$-125.0M
$12.2B
Q3 25
$14.0B
Q2 25
$321.0M
$13.9B
Q1 25
$27.0M
$14.7B
Q4 24
$-41.0M
$14.6B
Q3 24
$60.0M
$14.8B
Q2 24
$328.0M
$14.6B
Q1 24
$91.0M
$14.6B
Total Assets
CLX
CLX
IVZ
IVZ
Q4 25
$5.6B
$27.1B
Q3 25
$28.4B
Q2 25
$5.6B
$28.5B
Q1 25
$5.5B
$28.1B
Q4 24
$5.6B
$27.0B
Q3 24
$5.5B
$27.5B
Q2 24
$5.8B
$27.2B
Q1 24
$5.8B
$28.1B
Debt / Equity
CLX
CLX
IVZ
IVZ
Q4 25
0.15×
Q3 25
0.12×
Q2 25
7.74×
0.14×
Q1 25
0.07×
Q4 24
0.06×
Q3 24
0.06×
Q2 24
7.56×
0.06×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLX
CLX
IVZ
IVZ
Operating Cash FlowLast quarter
$455.8M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLX
CLX
IVZ
IVZ
Q4 25
$455.8M
Q3 25
$606.2M
Q2 25
$294.0M
$547.9M
Q1 25
$286.0M
$-84.6M
Q4 24
$180.0M
$316.9M
Q3 24
$221.0M
$438.4M
Q2 24
$340.0M
$489.1M
Q1 24
$182.0M
$-54.4M
Free Cash Flow
CLX
CLX
IVZ
IVZ
Q4 25
$432.2M
Q3 25
$586.4M
Q2 25
$219.0M
$530.4M
Q1 25
$233.0M
$-108.0M
Q4 24
$127.0M
$309.9M
Q3 24
$182.0M
$410.0M
Q2 24
$259.0M
$462.4M
Q1 24
$127.0M
$-75.4M
FCF Margin
CLX
CLX
IVZ
IVZ
Q4 25
25.5%
Q3 25
35.7%
Q2 25
11.0%
35.0%
Q1 25
14.0%
-7.1%
Q4 24
7.5%
19.5%
Q3 24
10.3%
27.1%
Q2 24
13.6%
31.2%
Q1 24
7.0%
-5.1%
Capex Intensity
CLX
CLX
IVZ
IVZ
Q4 25
1.4%
Q3 25
1.2%
Q2 25
3.8%
1.2%
Q1 25
3.2%
1.5%
Q4 24
3.1%
0.4%
Q3 24
2.2%
1.9%
Q2 24
4.3%
1.8%
Q1 24
3.0%
1.4%
Cash Conversion
CLX
CLX
IVZ
IVZ
Q4 25
Q3 25
1.70×
Q2 25
0.89×
2.78×
Q1 25
1.54×
-0.49×
Q4 24
0.93×
1.51×
Q3 24
2.23×
7.97×
Q2 24
1.57×
3.70×
Q1 24
-0.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLX
CLX

Health And Wellness$643.0M38%
Household$419.0M25%
Lifestyle$321.0M19%
Other$290.0M17%

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

Related Comparisons